Phase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC).
T. J. Semrad
No relevant relationships to disclose
C. Eddings
No relevant relationships to disclose
M. P. Dutia
No relevant relationships to disclose
S. Christensen
No relevant relationships to disclose
D. Lau
No relevant relationships to disclose
P. Lara
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - GlaxoSmithKline; Pfizer